CClinicalTrials.gg
CompletedNCT05506735PSAUpdated Aug 19, 2022

The Role of the Seven Sweeps in the Prevention of the Prostate Cancer Among Those With a Positive Family History

An observational study in Prostate Cancer, Prostatic Neoplasms and Prostatic Hyperplasia, sponsored by University of Baghdad. Completed at 1 site in Iraq. Open to male participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-19.

Sponsored by University of Baghdad · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
215
Ages
40 Years to 70 Years
Sex
Male
01

Study summary

The seven sweeps is a recommended act performed by men after urinating in order to be confident that no urine is left in the urethra, and its not compulsory to perform. It is performed by the following way: after urinating, the anus is first purified if it has become impure; then, the middle finger of the left hand is slid three times from the anus up to the scrotum; then, the thumb is placed on the penis and the forefinger is placed under the penis, and the thumb and forefinger are pulled three times along the penis up to the point of circumcision; finally, the end of the penis is pressed three times.

Read the detailed description

The investigators have investigated 350 people who have been doing this habit for at least 20 years of their life and they have a family history of prostatic cancer to check the effect of this procedure on the prevention of the cancer. The investigators have excluded 135 participants of them because they have not full-filled the criteria of inclusion. So 215 of them have been included and investigated using PSA and prostate ultrasound.

02

Conditions studied

  • Prostate Cancer
  • Prostatic Neoplasms
  • Prostatic Hyperplasia

Keywords

  • Prostate cancer
  • Prostate hyperplasia
  • The seven sweeps
03

In context

Prostatic Neoplasms

6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.

This study's enrollment of 215 is close to the median of 200 across 1,181 observational studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

University of Baghdad is the lead sponsor of 164 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
Male
Sampling method
Non-probability sample

Study population

We included 350 participants and 135 if them were excluded. Only 215 who full-filled the criteria were included.

Inclusion criteria

  • Family history of prostate cancer, more than 40 years of age, is doing the seven sweeps habit for at least 20 years, has not any urinary problems or chronic diseases.

Exclusion criteria

Exclusion Criteria:

  • No family history of prostate cancer, less than 40 years of age of more than 70 years old, has a urinary problem or chronic diseases.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
215 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prostate specific antigen

    PSA is a protein made by the prostate gland. The amount of PSA may be higher in men who have prostate cancer, benign prostatic hyperplasia (BPH), or infection or inflammation of the prostate. Also called prostate-specific antigen test.

    Time frame: 30 minutes

Secondary outcomes

  1. Prostate ultrasound

    Using the sonography to locate and measure the thickness and the tissue of the prostate.

    Time frame: 30 minutes

07

Study locations

1 site
  • Al-Dar medical Center
    Nasiriyah, Thi Qar 64001, Iraq
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05506735
Lead sponsor
University of Baghdad
Responsible party
Hashim Talib Hashim (Doctor (MBChB), University of Baghdad) — Principal investigator
First posted
Aug 18, 2022
Start date
May 1, 2022
Primary completion
Aug 17, 2022
Completion
Aug 17, 2022
Last update
Aug 19, 2022

Study contacts

Hashim Talib T Hashim, MBChB
principal investigator · University of Baghdad, College of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion